You are here: Welcome to the MPKB » Welcome to the MPKB » Health, food and drink » Aiming at Health » Health Maintenance and Olmesartan
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:food:aim_health:aging [02.25.2019] – [A number of studies have found] sallieqhome:food:aim_health:aging [05.17.2019] – [Health Maintenance and Olmesartan] sallieq
Line 5: Line 5:
 Summary of research on aging and Olmesartan Summary of research on aging and Olmesartan
 taken from article [[home:protocol:olmesartan|Science behind olmesartan ]] taken from article [[home:protocol:olmesartan|Science behind olmesartan ]]
 +
 +<relatedarticles> [[home:pathogenesis:innate_immunity|Innate immunity]] , [[home:food:aim_health|Keep the health you have]]  </article>
  
 ===== with additional studies ===== ===== with additional studies =====
Line 15: Line 17:
  
  Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued.  (({{pubmed>long:24772521}}))  Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued.  (({{pubmed>long:24772521}}))
 +
 +Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells.   (in breast cancer)(({{pubmed>long:    26138656}}))
  
 Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>long:27082551}}))  Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>long:27082551}})) 
Line 20: Line 24:
 Administration of olmesartan suppressed the accumulation of macrophages in  brachiocephalic atherosclerotic plaque. (in mice) (({{pubmed>long:    20079903}}))  Administration of olmesartan suppressed the accumulation of macrophages in  brachiocephalic atherosclerotic plaque. (in mice) (({{pubmed>long:    20079903}})) 
  
-Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) +Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) (({{pubmed>long:    20074257}}))
  
 Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.  (({{pubmed>long:24379062}}))  Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.  (({{pubmed>long:24379062}})) 
home/food/aim_health/aging.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.